REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.26+0.02 (+0.28%)
Close on Nov 18, 2026Market cap $479.26MP/E –Yield –
Regenxbio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Regenxbio's revenue for the twelve months ending Jun 30, 2026 was $174.48M, up 12.0% year over year. For fiscal 2025 it was $170.44M, up 104.5% from the year before. Over ten years it grew 36.5% a year on average. The highest annual figure on record is $470.35M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.44M | +104.5% |
| FY2024 | Dec 31, 2024 | $83.33M | -7.7% |
| FY2023 | Dec 31, 2023 | $90.24M | -19.9% |
| FY2022 | Dec 31, 2022 | $112.72M | -76.0% |
| FY2021 | Dec 31, 2021 | $470.35M | +204.3% |
| FY2020 | Dec 31, 2020 | $154.57M | +338.7% |
| FY2019 | Dec 31, 2019 | $35.23M | -83.9% |
| FY2018 | Dec 31, 2018 | $218.51M | +2002.4% |
| FY2017 | Dec 31, 2017 | $10.39M | +126.5% |
| FY2016 | Dec 31, 2016 | $4.59M | -39.5% |
| FY2015 | Dec 31, 2015 | $7.59M | +24.0% |
| FY2014 | Dec 31, 2014 | $6.12M | +0.5% |
| FY2013 | Dec 31, 2013 | $6.09M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $108.02M | +405.7% |
| Q1 FY2026 | Mar 31, 2026 | $6.39M | -92.8% |
| Q4 FY2025 | Dec 31, 2025 | $30.34M | +43.0% |
| Q3 FY2025 | Sep 30, 2025 | $29.73M | +22.9% |
| Q2 FY2025 | Jun 30, 2025 | $21.36M | -4.2% |
| Q1 FY2025 | Mar 31, 2025 | $89.01M | +469.8% |
| Q4 FY2024 | Dec 31, 2024 | $21.21M | -4.5% |
| Q3 FY2024 | Sep 30, 2024 | $24.20M | -16.3% |
| Q2 FY2024 | Jun 30, 2024 | $22.30M | +11.6% |
| Q1 FY2024 | Mar 31, 2024 | $15.62M | -18.4% |
| Q4 FY2023 | Dec 31, 2023 | $22.21M | -29.1% |
| Q3 FY2023 | Sep 30, 2023 | $28.91M | +9.1% |
| Q2 FY2023 | Jun 30, 2023 | $19.98M | -38.8% |
| Q1 FY2023 | Mar 31, 2023 | $19.14M | -13.9% |
| Q4 FY2022 | Dec 31, 2022 | $31.35M | -92.1% |
| Q3 FY2022 | Sep 30, 2022 | $26.51M | -13.8% |
| Q2 FY2022 | Jun 30, 2022 | $32.65M | +48.2% |
| Q1 FY2022 | Mar 31, 2022 | $22.22M | +17.7% |
| Q4 FY2021 | Dec 31, 2021 | $398.66M | +1759.0% |
| Q3 FY2021 | Sep 30, 2021 | $30.77M | -68.9% |
| Q2 FY2021 | Jun 30, 2021 | $22.04M | +33.0% |
| Q1 FY2021 | Mar 31, 2021 | $18.88M | +7.0% |
| Q4 FY2020 | Dec 31, 2020 | $21.45M | +82.2% |
| Q3 FY2020 | Sep 30, 2020 | $98.91M | +572.9% |
| Q2 FY2020 | Jun 30, 2020 | $16.57M | +110.2% |
| Q1 FY2020 | Mar 31, 2020 | $17.64M | +1895.9% |
| Q4 FY2019 | Dec 31, 2019 | $11.77M | -71.1% |
| Q3 FY2019 | Sep 30, 2019 | $14.70M | +177.0% |
| Q2 FY2019 | Jun 30, 2019 | $7.88M | -80.3% |
| Q1 FY2019 | Mar 31, 2019 | $884.00K | -99.3% |
| Q4 FY2018 | Dec 31, 2018 | $40.78M | +1898.9% |
| Q3 FY2018 | Sep 30, 2018 | $5.31M | +297.2% |
| Q2 FY2018 | Jun 30, 2018 | $40.03M | +510.0% |
| Q1 FY2018 | Mar 31, 2018 | $132.39M | +28996.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.04M | +20.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.34M | +968.8% |
| Q2 FY2017 | Jun 30, 2017 | $6.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $455.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.70M | – |
| Q3 FY2016 | Sep 30, 2016 | $125.00K | – |
See a number that looks wrong?